PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsBoceprevir
Victrelis(boceprevir)
Victrelis (boceprevir) is a small molecule pharmaceutical. Boceprevir was first approved as Victrelis on 2011-05-13. It is used to treat chronic hepatitis c and hepatitis c in the USA. It has been approved in Europe to treat chronic hepatitis c. It is known to target lysosomal protective protein.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
digestive system diseasesD004066
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Boceprevir
Tradename
Company
Number
Date
Products
VICTRELISMerck & CoN-202258 DISCN2011-05-13
1 products
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
hepatitis c—D006526B19.2
chronic hepatitis cEFO_0004220D019698B18.2
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Boceprevir, Victrelis, Merck Sharp Dohme
77721782027-11-11DPU-1128
81196022027-03-17U-1233
RE432982024-12-22DS, DPU-1128
ATC Codes
J: Antiinfectives for systemic use
— J05: Antivirals for systemic use
— J05A: Direct acting antivirals
— J05AP: Antivirals for treatment of hcv infections
— J05AP03: Boceprevir
HCPCS
No data
Clinical
Clinical Trials
68 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hepatitis cD006526—B19.29112161560
HepatitisD006505HP_0012115K75.9292071349
Hepatitis aD006506EFO_0007305B1528177840
Chronic hepatitis cD019698EFO_0004220B18.218185939
Hiv infectionsD015658EFO_0000764B20232119
Chronic hepatitisD006521—K73.9—261—9
HivD006678———1—124
Chronic kidney failureD007676EFO_0003884N18.9———112
Kidney diseasesD007674EFO_0003086N08———112
HomozygoteD006720—————1—1
Show 1 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
InfectionsD007239EFO_0000544—223—29
Communicable diseasesD003141——122——5
CoinfectionD060085———11——2
HepacivirusD016174——111——2
Chronic hepatitis bD019694EFO_0004239B18.1——1—12
ThrombocytopeniaD013921HP_0001873D69.6111——2
MenopauseD008593EFO_0003922N95——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Liver cirrhosisD008103EFO_0001422K74.0—1——23
Acquired immunodeficiency syndromeD000163EFO_0000765B2011——13
Healthy volunteers/patients———31———3
FibrosisD005355———1———1
Experimental liver cirrhosisD008106———1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Papillomavirus infectionsD030361——2————2
Liver transplantationD016031EFO_0010682—1————1
HypertensionD006973EFO_0000537I101————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameBoceprevir
INNboceprevir
Description
Boceprevir is a synthetic tripeptide consisting of N-(tert-butylcarbamoyl)-3-methyl-L-valyl, a cyclopropyl-fused prolyl and 3-amino-4-cyclobutyl-2-oxobutanamide residues joined in sequence. Used for treatment of chronic hepatitis C virus genotype 1 infection. It has a role as a hepatitis C protease inhibitor, a peptidomimetic and an antiviral drug. It is a tripeptide and a member of ureas.
Classification
Small molecule
Drug classantivirals: serine protease inhibitors
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)NC(CC1CCC1)C(=O)C(N)=O)C2(C)C)C(C)(C)C
Identifiers
PDB—
CAS-ID394730-60-0
RxCUI—
ChEMBL IDCHEMBL218394
ChEBI ID68621
PubChem CID10324367
DrugBankDB08873
UNII ID89BT58KELH (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
CTSA
CTSA
Organism
Homo sapiens
Gene name
CTSA
Gene synonyms
PPGB
NCBI Gene ID
5476
Protein name
lysosomal protective protein
Protein synonyms
beta-galactosidase 2, beta-galactosidase protective protein, Carboxypeptidase C, Carboxypeptidase L, carboxypeptidase Y-like kininase, carboxypeptidase-L, Cathepsin A, deamidase, lysosomal carboxypeptidase A, PPCA, Protective protein cathepsin A, Protective protein for beta-galactosidase, urinary kininase
Uniprot ID
Q9BW68
Mouse ortholog
Ctsa (19025)
lysosomal protective protein (Q8VEF6)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Boceprevir
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 4,242 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
10,157 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use